Protocol: CDISCPILOT01                                                                  Page  1 of 1 
Population: All Subjects 
Table 14-1.01 
Summary of Populations 
 
 
NOTE: N in column headers represents number of subjects entered in study (i.e., signed informed consent). 
The ITT population includes all subjects randomized.  The Safety population includes all randomized 
subjects known to have taken at least one dose of randomized study drug. The Efficacy population includes 
all subjects in the safety population who also have at least one post-baseline ADAS-Cog and CIBIC+ 
assessment. 
Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\adsl1.sas                     21:02 Monday, June 26, 2006 
 
Placebo 
(N=86) 
Xanomeline 
Low Dose 
(N=84) 
Xanomeline
High Dose
(N=84) 
Total 
(N=254) 
Intent-To-Treat (ITT) 
 86 (100%)
 84 (100%)
 84 (100%)
254 (100%)
Safety 
 86 (100%)
 84 (100%)
 84 (100%)
254 (100%)
Efficacy 
 79 ( 92%)
 81 ( 96%)
 74 ( 88%)
234 ( 92%)
Complete Week 24 
 60 ( 70%)
 28 ( 33%)
 30 ( 36%)
118 ( 46%)
Complete Study 
 58 ( 67%)
 25 ( 30%)
 27 ( 32%)
110 ( 43%)
 
